Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today
03:38pm, Tuesday, 30'th Dec 2025
A Wells Fargo analyst cut his price target on Ultragenyx stock, though it still implies significant upside from yesterday's closing price. Ultragenyx reported yesterday that two Phase 3 studies failed
Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm
02:24pm, Tuesday, 30'th Dec 2025
LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ultragenyx Pharmaceutical, Inc. (“Ultragenyx" or the "Company") (NASDAQ: RARE) investors that the firm has initiated an in
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint
12:00pm, Tuesday, 30'th Dec 2025
Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.
Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain
09:52am, Tuesday, 30'th Dec 2025
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares plunged 42% on Monday after the company and partner Mereo BioPharma Group plc (NASDAQ: MREO) disclosed disappointing late-stage data for their rare
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
03:14pm, Monday, 29'th Dec 2025
Ultragenyx Pharmaceuticals reported Phase 3 results for setrusumab, a potential treatment for osteogenesis imperfecta. Several firms have reduced their price targets on Ultragenyx stock.
Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows
10:15am, Monday, 29'th Dec 2025
Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta treatment.
Ultragenyx's bone disease drug fails late-stage trials
08:35am, Monday, 29'th Dec 2025
Ultragenyx Pharmaceutical said on Monday that its experimental drug for a type of genetic bone disease did not meet the main goal in late-stage studies.
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
08:30am, Monday, 29'th Dec 2025
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 19'th Dec 2025
NOVATO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
Tactical Resources Announces Receipt Of Final Order Approving Arrangement With Plum Acquisition Corp. III
09:15pm, Thursday, 18'th Dec 2025
VANCOUVER, BC / ACCESS Newswire / December 18, 2025 / Tactical Resources Corp. (TSXV:RARE)(OTC PINK:USRED) ("Tactical" or the "Company"), a mineral exploration and development company, is pleased to a
Tactical Resources Announces Shareholder Approval of Arrangement With Plum Acquisition Corp. III
05:20pm, Tuesday, 16'th Dec 2025
VANCOUVER, BC / ACCESS Newswire / December 16, 2025 / Tactical Resources Corp. (TSXV:RARE)(OTC PINK:USRED) ("Tactical" or the "Company"), a mineral exploration and development company, is pleased to a
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings
11:30pm, Sunday, 14'th Dec 2025
Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materiall
Frontier Capital Management Co. LLC Invests $19.11 Million in Ultragenyx Pharmaceutical Inc. $RARE
04:12am, Friday, 12'th Dec 2025
Frontier Capital Management Co. LLC bought a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) during the second quarter, according to the company in its most recent filing with
CENTURY LITHIUM HIGHLIGHTS RARE EARTH POTENTIAL AT ANGEL ISLAND, NEVADA
08:30am, Thursday, 11'th Dec 2025
VANCOUVER, BC , Dec. 11, 2025 /PRNewswire/ - Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) ("Century Lithium" or "the Company") is pleased to provide further details regarding its
